HomeCompareLPMDF vs ABBV

LPMDF vs ABBV: Dividend Comparison 2026

LPMDF yields 33333.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LPMDF wins by $36877558.94M in total portfolio value
10 years
LPMDF
LPMDF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36877559.04M
Annual income
$5,235,992,218,813.37
Full LPMDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LPMDF vs ABBV

📍 LPMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPMDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPMDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPMDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPMDF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$4,450,593,385,991.36/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LPMDF beats the other by $4,450,593,364,935.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPMDF + ABBV for your $10,000?

LPMDF: 50%ABBV: 50%
100% ABBV50/50100% LPMDF
Portfolio after 10yr
$18438779.57M
Annual income
$2,617,996,121,792.57/yr
Blended yield
14.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LPMDF
No analyst data
Altman Z
0.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPMDF buys
0
ABBV buys
0
No recent congressional trades found for LPMDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPMDFABBV
Forward yield33333.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$36877559.04M$102.3K
Annual income after 10y$5,235,992,218,813.37$24,771.77
Total dividends collected$32285303.33M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LPMDF vs ABBV ($10,000, DRIP)

YearLPMDF PortfolioLPMDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,677,367$1,666,666.67$11,550$430.00+$1.67MLPMDF
2$132,430,816$130,636,033.23$13,472$627.96+$132.42MLPMDF
3$4,961,292,770$4,819,591,797.06$15,906$926.08+$4961.28MLPMDF
4$89,681,348,983$84,372,765,719.75$19,071$1,382.55+$89681.33MLPMDF
5$808,641,040,801$712,681,997,389.07$23,302$2,095.81+$808641.02MLPMDF
6$3,868,109,904,567$3,002,863,990,909.25$29,150$3,237.93+$3868109.88MLPMDF
7$10,851,078,003,552$6,712,200,405,665.56$37,536$5,121.41+$10851077.97MLPMDF
8$20,409,489,435,000$8,798,835,971,199.81$50,079$8,338.38+$20409489.38MLPMDF
9$29,571,557,777,933$7,733,404,082,483.14$69,753$14,065.80+$29571557.71MLPMDF
10$36,877,559,041,202$5,235,992,218,813.37$102,337$24,771.77+$36877558.94MLPMDF

LPMDF vs ABBV: Complete Analysis 2026

LPMDFStock

LMIR Trust is a Singapore-based real estate investment trust established with the principal investment objective of owning and investing, on a long-term basis, in a diversified portfolio of income-producing real estate in Indonesia that are primarily used for retail and/or retail-related purposes. LMIR Trust's current asset portfolio comprises 21 retail malls ("Retail Malls") and seven retail spaces located within other retail malls ("Retail Spaces", and collectively with the Retail Malls, the "Properties"). The Properties have a total net lettable area of 839,907 square metres and total valuation of Rp15,716.1 billion as at 31 July 2020, and are strategically located in major cities of Indonesia with large middle-income population. Tenants include leading names such as Matahari Department Store, Zara, M&S, H&M, Sogo, Giant, Hypermart, Carrefour, Ace Hardware, as well as international specialty tenants such as Victoria's Secret, Promod, McDonalds, Pizza Hut, Kentucky Fried Chicken, A&W, Fitness First and Starbucks.

Full LPMDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LPMDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPMDF vs SCHDLPMDF vs JEPILPMDF vs OLPMDF vs KOLPMDF vs MAINLPMDF vs JNJLPMDF vs MRKLPMDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.